Keywords: Hybrid & Novel Systems Technology, Magnetization transfer, Magnetic particle spectroscopy, MPS, COMPASS, contrast agents, iron oxide based
Motivation: Contrast agents allow a significant improvement of MRI performance. Resotran is a new iron oxide-based and biocompatible MRI contrast agent that is now commercially available in Europe, which still needs to be characterized in more detail.
Goal(s): Classification of the performance of Resotran compared to Resovist.
Approach: Analyzation and characterization with various spectroscopic and imaging methods.
Results: Resotran shows a comparable performance to the former liver contrast agent Resovist. Furthermore, it was shown that Resotran is feasible as a tracer for the new imaging modality magnetic particle imaging (MPI). This is an important step towards paving the way for MPI in clinical routine.
Impact: In this work it is shown that the new clinically approved contrast agent Resotran shows a comparable performance as the well-known contrast agent Resovist by a detailed comparison applying different spectroscopic characterization methods.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords